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Abstract 
Onchocerciasis and lymphatic filariasis are two neglected tropical diseases (NTDs) that 
together affect ~157 million people and inflict severe disability. Both diseases are caused by 
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parasitic filarial nematodes with elimination efforts constrained by lack of a safe drug that 
can kill the adult filaria (macrofilaricide). Previous proof-of-concept human trials have 
demonstrated that depleting >90% of the essential nematode endosymbiont bacterium, 
Wolbachia, using antibiotics, can lead to permanent sterilisation of adult female parasites 
and a safe macrofilaricidal outcome. AWZ1066S is a highly specific anti-Wolbachia 
candidate selected through a lead optimisation programme focused on balancing efficacy, 
safety and drug metabolism/pharmacokinetic (DMPK) features of a 
thienopyrimidine/quinazoline scaffold derived from phenotypic screening. AWZ1066S shows 
superior efficacy to existing anti-Wolbachia therapies in validated preclinical models of 
infection and has DMPK characteristics that are compatible with a short therapeutic regimen 
of seven days or less. This candidate molecule is well-positioned for onward development 
and has the potential to make a significant impact to communities affected by filariasis. 
Significance 
Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) are neglected 
tropical diseases that cause severe disability and affect more than 157 million people 
globally. The current control efforts are hindered by the lack of a safe macrofilaricidal drug 
that can eliminate the parasitic adult nematodes safely. A clinically validated approach for 
delivering macrofilaricidal activity is to target the Wolbachia bacterial endosymbiont of the 
causative nematodes. This first-in-class, highly potent and specific anti-Wolbachia pre-
clinical candidate molecule, AWZ1066S has the potential to significantly impact current 
global onchocerciasis and lymphatic filariasis elimination programmes and to reduce 
elimination time frames from decades to years. 
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Introduction 
Onchocerciasis (river blindness) and lymphatic filariasis (elephantiasis) continue to inflict 
serious public health problems throughout tropical communities, globally affecting more than 
38 million and 120 million people, respectively. These two NTDs are caused by parasitic 
filarial nematodes Onchocerca volvulus (onchocerciasis), Wuchereria  bancrofti, Brugia 
malayi, and Brugia timori (lyphatic filariasis).(1) Global programmes for control and 
elimination have been developed, but existing approaches target only microfilaria and 
require prolonged delivery with high treatment coverage to break the transmission cycle of 
the long-lived adult worm.(2, 3) This inability of current drugs to kill adult parasites has 
highlighted the need for new macrofilaricidal drugs. 
Wolbachia are essential for multiple components of filarial nematode biology including larval 
growth, development, embryogenesis and, ultimately, survival of many filarial nematodes, 
including the causative parasites of onchocerciasis and lyphatic filariasis, making this 
symbiont a validated chemotherapeutic target.(4, 5) Although the macrofilaricidal activity of 
doxycycline through depletion of Wolbachia has been proven clinically (6-12), protracted 
treatment regimens (≥28 days) and contraindications restrict its widespread 
implementation.(13, 14)  
Results 
Lead optimization led to the selection of AWZ1066S as preclinical candidate 
To identify novel anti-Wolbachia chemotypes, we screened 10,000 compounds selected 
from the BioFocus Soft-Focus library using a phenotypic cell-based screen incorporating a 
Wolbachia-infected Aedes albopictus cell line [C6/36 (wAlbB)] as reported previously.(15) 
From this screen we identified and confirmed 50 anti-Wolbachia active hits (0.5% hit rate) 
that clustered into six unique chemotypes. Based on an evaluation of drug-like properties 
and potency, we selected a series of thienopyrimidines for medicinal chemistry optimisation. 
Through a highly integrated academic-industrial partnership, multi-parameter lead 
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optimisation was performed with over 300 analogues synthesised and assessed for both 
anti-Wolbachia activity and DMPK properties (LogD, aqueous solubility, plasma protein 
binding, microsomal and hepatocyte stability) in vitro.(16) In this process, we transformed 
the thienopyrimidine core of the starting hit molecule into quinazoline AWB158 and 
eventually azaquinazoline AWZ1066, resolving the metabolic weakness associated with the 
original scaffold whilst improving potency. Optimisation of the 2-position of the 
azaquinazoline core led to AWZ1066 which was selected as a front runner (Fig 1a, see SI 
Appendix Figure S1 for detailed structural-activity relationship analyses of this series). 
AWZ1066 was active against Wolbachia in a cell-based assay(17) with an EC50 of 2.6 ± 0.5 
nM (Fig 1b). In an orthogonal secondary in vitro assay utilising microfilariae (mf) of the 
human parasite Brugia malayi, AWZ1066 reduced Wolbachia within the mf with an EC50 of 
150 nM whilst had no effect of the viability and motility of the mf at up to the top testing 
concentration of 5 µM. 
Specific structural features of AWZ1066, such as the lipophilic electron withdrawing CF3 
group in the 4-position side-chain, the nitrogen at the 8-position of the azaquinazoline core 
and the methyl group in the 2-position of the morpholinyl side-chain contribute significantly to 
potency in both assays (SI Appendix Figure S1). Matched pair analyses with or without 
these individual structural features demonstrated a 10 – 100 fold potency loss. AWZ1066 
has two enantiomers, namely AWZ1066S and AWZ1066R, demonstrating minor differences 
in anti-Wolbachia potency in vitro with the (S)-isomer, AWZ1066S the more potent of the 
enantiomers in both in vitro assays (EC50s: Cell assay: 2.5 ± 0.4 nM vs. 14.4 ± 3.7 nM; mf 
assay: 122 nM vs. 408 nM) (Fig 1c). The predicted cost of goods for AWZ1066 and its 
enantiomers are considered to be low based on two simple sequential amination steps from 
readily available 2,4-dichloropyrido[2,3-d]pyrimidine (SI Appendix Figure S1). This will 
support cost efficient large-scale synthesis. 
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Extensive comparative analysis of the two enantiomers led to the selection of the (S)-
enantiomer, AWZ1066S, as the preclinical candidate based on superiority in terms of in vitro 
potency, in vivo efficacy and safety pharmacology (vide infra). 
Pharmacokinetics, pharmacodynamics and safety profiles of AWZ1066S match anti-
Wolbachia macrofilaricide Target Candidate Profile (TCP) 
A key criterion for anti-Wolbachia macrofilaricides is the need for oral drug delivery, 
necessitating good aqueous solubility and metabolic stability. AWZ1066S meets the desired 
physicochemical properties with acceptable solubility in both PBS buffer (238 µM) and fasted 
state simulated intestinal fluid (FaSSIF) (0.56 mg/ml), moderate human plasma protein 
binding (91%) and ready formulation as a salt (pKa = 5.6) (Fig 1d). The metabolic turnover of 
AWZ1066S by both liver microsomes and hepatocytes across a range of different species, 
including mouse, rat, dog, monkey and human is low and negatively correlated with the 
species body size (SI Appendix Table S3). High metabolic stability was also observed in the 
in vivo mouse PK profile (total clearance = 0.47 L/hr/kg and T1/2 = 3.5 hours) when dosed 
intravenously. The permeability of AWZ1066S in a LLC-PK1 cell assay is good (Papp = 7.4 X 
106 cm/s) and despite being a mammalian P-gp transporter substrate (P-gp mediated efflux 
ratio = 7.8), AWZ1066S showed good to excellent oral bioavailability (range 54 – 91 %) 
across a range of dosages up to 250 mg/kg in the mouse (SI Appendix Table S4). 
AWZ1066S is a weak CYP2C9 inhibitor (IC50 = 9.7 µM) and a weak CYP3A4 inducer (IC50 = 
37 µM) but does not show any time-dependent inhibition across 5 major human CYP450 
isoforms (CYP1A, CYP2C9, CYP2C19, CYP2D6, CYP3A). 
One of the major limitations of doxycycline, the current “gold standard” anti-Wolbachia 
macrofilaricide in the treatment of filariasis, is its prolonged treatment period of 4 – 6 weeks 
to deliver a cure.(6, 9, 10, 12) The community consensus is that novel macrofilaricide 
treatments need to be implementable in seven days or less.(5, 14) To assess if AWZ1066S 
could meet this demand, determined as a threshold reduction of Wolbachia >90% in seven 
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days, efficacy was evaluated in two independent animal models of filarial infection. As an 
initial screen, we used the adult Brugia malayi SCID mouse model.(14) In this model, human 
bioequivalent exposures to 100 mg/day doxycycline require 6 weeks to mediate >90% 
Wolbachia depletion within female B. malayi adult parasites, whilst the more potent second 
generation tetracycline, minocycline, still requires 4 weeks exposure bioequivalent to 100 
mg/day dosing to mediate similar efficacy.(18, 19) AWZ1066S (100 mg/kg) reduced 
Wolbachia by 98% after only seven days orally administrated treatment (compared to vehicle 
group) (Kruskal Wallis statistic 50.7, P<0.0001 Fig 2a). Furthermore, the release of mf was 
completely prevented in 9/10 mice treated with AWZ1066S over the 6 weeks of observation 
post treatment (SI Appendix Table S5). We further investigated the preclinical efficacy of 7-
day AWZ1066S dosing in a second rodent filarial infection system (Litomosoides 
sigmodontis gerbil model(20)). After seven days of twice-daily treatment of AWZ1066S at 
either 100 or 50 mg/kg orally, Wolbachia load was reduced by >99% compared to control 
untreated animals, 18 weeks post-treatment (Kruskal Wallis statistic 43.5, P<0.0001, Fig 2b). 
In this model, mf produced by female adult worms circulate in the blood and thus peripheral 
microfilaremias can be tracked longitudinally post-treatment. After AWZ1066S treatment the 
peripheral blood microfilaremia began to decline from 6 weeks post treatment. A state of 
amicrofilaremia (absence of mf in blood) was evident from 14 weeks post-treatment in the 7-
day AWZ1066S treatment groups, a state that was sustained until the end of the experiment 
at 18 weeks post-treatment. Thus, treatment with AWZ1066S for seven days leads to 
sterilisation, gradual depletion of mf with the assumption, based on extensive clinical trial 
data with doxycycline, that this will result in a ‘slow’ killing of adult worms alongside an 
improved safety profile. Based on PK/PD modelling(21) of the available data, using human 
PK simulations, we predict that >90% of a patient population will achieve a 90% or higher 
Wolbachia reduction (considered fully efficacious clinically(8, 10, 22)) within seven days 
using an oral dose of 10 mg per kg body weight of AWZ1066S in human (Fig 2d, SI 
Appendix Table S6). 
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AWZ1066S was subsequently tested for safety pharmacology characteristics. AWZ1066S 
showed very low cytotoxicity in multiple in vitro toxicology assays (SI Appendix Table S7). 
AWZ1066S was also tested against a panel of 25 well characterised human protein 
assays(23) (CEREP panel) in vitro to assess secondary pharmacology. The CEREP panel 
screen results indicated low promiscuity across the panel (SI Appendix Table S8). 
AWZ1066S was negative in both the Ames test and the in vivo micronucleus assay in the 
mouse (SI Appendix Table S9). AWZ1066 was also evaluated for cardiovascular safety both 
in vitro (hERG and Nav1.5) and in vivo (anesthetised and conscious rats, SI Appendix Table 
S10) demonstrating a low risk. In a preliminary 7-day dose range finding (DRF) study in the 
rat (SI Appendix Table S11), the no observed adverse effect level (NOAEL) for AWZ1066  
was determined to be >300 mg/kg. 
Discussion 
The antibacterial activity profile of AWZ1066S was examined against a panel of clinically 
relevant bacterial strains, including gram-positive and gram-negative species and strains 
with known drug resistance profiles. The data indicated that AWZ1066S is highly specific for 
Wolbachia (SI Appendix Table S12). This high specificity of AWZ1066S against Wolbachia is 
a significant advantage as it would predict minimal impact on the gut microbiota, lowering the 
risk of dysbiosis and the selection and emergence of resistance following administration to 
patients, in comparison to other anti-Wolbachia based broad spectrum antibiotic treatments.  
In addition to the ability to elicit efficacy after seven days of treatment, AWZ1066 also has a 
faster kill rate compared to other known antibiotics tested against Wolbachia in vitro. In a 
time-kill assay modified from the standard mf assay, a panel of anti-Wolbachia drugs(24) 
including moxifloxacin, rifampicin, minocycline, doxycycline and AWZ1066S were screened 
over a range of exposure intervals (1, 2 and 6 days). The results show AWZ1066S can 
achieve maximum reduction of Wolbachia just after one day of drug exposure compared to 
the other antibiotics tested (1 – 6 days of exposure, Figure 3a). These results further support 
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the potential of AWZ1066S to deliver treatment time frames <7 days. Furthermore, 
differential time to kill profiles suggest a novel mode of action for the AWZ1066S class 
compared to antibiotics that work via inhibition of aspects of protein synthesis. Genetic 
approaches to identify the molecular target(s) of AWZ1066S have been thwarted by the 
intractability of this intracellular bacterium. However, using a proteomic approach with 
photoreactive chemical probes we have identified a number of credible Wolbachia and host 
proteins that are being evaluated as potential drug targets of AWZ1066S (Fig 3b and c, SI 
Dataset S1).  
In conclusion, starting with a hit chemotype from a modest scale whole cell screen, a 
medicinal chemistry led scaffold hopping and multi-parameter optimisation programme has 
delivered the first novel synthetic candidate molecule, AWZ1066S that is highly specific 
against Wolbachia. Seven-day oral dosing regimens with AWZ1066S is capable of depleting 
Wolbachia >90% with sustained sterilisation of mf production in two independent filarial 
infection models. This candidate selected molecule meets all Target Candidate Profile 
criteria for an anti-Wolbachia macrofilaricidal drug and has entered formal preclinical 
evaluation. AWZ1066S has the potential to deliver a novel anti-filarial therapy that could be 
deployed in target populations in a sub-seven-day dosing regimen. The compound provides 
a unique opportunity to make a significant contribution to communities affected by filariasis 
especially if the predicted macrofilaricidal effect can be confirmed in clinical trials.  
Materials and Methods 
The chemical characterization of AWB158, AWZ1066S (and its HCl salt), and 
Photoreactive probe 1 & 2 
(Please see Supplementary Information for the synthesis of AWB158, AWZ1066S (and its 
HCl salt), and Photoreactive probe 1 & 2.) 
N2-isopropyl-N4-(2-(trifluoromethyl)benzyl)quinazoline-2,4-diamine (AWB158). 1H NMR 
(400 MHz, MeOD) δ 8.23 (d, J = 8.0 Hz, 1H), 7.89 – 7.81 (m, 1H), 7.78 (d, J = 7.8 Hz, 1H), 
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7.61 (t, J = 7.5 Hz, 1H), 7.56 – 7.42 (m, 4H), 5.11 (s, 2H), 4.18 – 4.06 (m, 1H), 1.13 (br, 6H); 
HRMS (ES) C19H20N4F3 [M+H]
+ requires 361.1640, found 361.1648; purity by HPLC 97.2%, 
Rt = 9.255 min. 
(S)-2-(3-methylmorpholino)-N-((2-(trifluoromethyl)pyridin-3-yl)methyl)pyrido[2,3-
d]pyrimidin-4-amine (AWZ1066S). 1H NMR (400 MHz, DMSO) δ 8.98 (t, J = 5.1 Hz, 1H), 
8.70 (d, J = 4.4 Hz, 1H), 8.60 (d, J = 4.3 Hz, 1H), 8.50 (d, J = 8.0 Hz, 1H), 7.95 (d, J = 7.9 Hz, 
1H), 7.64 (dd, J = 8.0, 4.6 Hz, 1H), 7.15 (dd, J = 8.0, 4.5 Hz, 1H), 4.94 (dd, J = 16.3, 4.7 Hz, 
1H), 4.79 (dd, J = 16.3, 4.8 Hz, 1H), 4.45 (m, 1H), 4.21 (d, J = 13.1 Hz, 1H), 3.82 (d, J = 11.1 
Hz, 1H), 3.58 (d, J = 11.3 Hz, 1H), 3.44 (d, J = 11.3 Hz, 1H), 3.32 – 3.23 (m, 1H), 2.99 (td, J 
= 13.2, 3.7 Hz, 1H), 0.87 (br, 3H); HRMS (ES) C19H19N6OF3 [M+H]
+ requires 405.1645, 
found 405.1641; purity by HPLC 97.8%, Rt = 7.147 min. AWZ1066S HCl salt
 1H NMR (400 
MHz, DMSO) δ 10.49 (s, 1H), 9.24 (d, J = 7.8 Hz, 1H), 9.02 – 8.69 (m, 1H), 8.64 (d, J = 4.4 
Hz, 1H), 8.05 (d, J = 7.9 Hz, 1H), 7.67 (dd, J = 7.9, 4.6 Hz, 1H), 7.52 (dd, J = 7.8, 5.6 Hz, 
1H), 4.97 (dd, J = 15.9, 4.4 Hz, 1H), 4.88 (dd, J = 15.9, 3.9 Hz, 1H), 4.50 (m, 1H), 4.26 (d, J 
= 13.1 Hz, 1H), 3.88 (d, J = 10.1 Hz, 1H), 3.62 (t, J = 17.2 Hz, 1H), 3.55 – 3.13 (m, 4H), 0.98 
(br, 3H). 
2-(1-(4-(((2-(trifluoromethyl)pyridin-3-yl)methyl)amino)pyrido[2,3-d]pyrimidin-2-
yl)piperidin-4-yl)ethyl (2-(3-(but-3-yn-1-yl)-3H-diazirin-3-yl)ethyl)carbamate 
(Photoreactive probe 1). 1H NMR (400 MHz, CDCl3) δ 8.75 (d, J = 4.3 Hz, 1H), 8.61 (d, J = 
4.4 Hz, 1H), 7.94 (d, J = 7.7 Hz, 1H), 7.86 (d, J = 7.9 Hz, 1H), 7.44 (dd, J = 7.9, 4.7 Hz, 1H), 
6.98 (dd, J = 7.9, 4.5 Hz, 1H), 6.10 (t, J = 5.4 Hz, 1H), 5.02 (d, J = 5.6 Hz, 2H), 4.90 – 4.73 
(m, 2H), 4.11 (t, J = 6.2 Hz, 2H), 3.05 (dd, J = 12.0, 5.7 Hz, 2H), 2.83 (t, J = 12.2 Hz, 2H), 
2.10 – 1.88 (m, 2H), 1.80 – 1.62 (m, 7H), 1.59 – 1.47 (m, 4H), 1.10 (br, 2H); HRMS (ES) 
C29H33N9O2F3 [M+H]
+ requires 596.2704, found 596.2709; purity by HPLC 90.3%, Rt =  8.888 
min. 
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2-(1-(4-(((2-(trifluoromethyl)pyridin-3-yl)methyl)amino)pyrido[2,3-d]pyrimidin-2-
yl)piperidin-4-yl)ethyl (1-oxo-1-((4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)benzyl)amino)pent-4-yn-2-yl)carbamate (Photoreactive probe 2). 1H NMR (400 MHz, 
CDCl3) δ 8.75 (d, J = 4.3 Hz, 1H), 8.61 (d, J = 4.3 Hz, 1H), 8.04 – 7.86 (m, 2H), 7.44 (dd, J = 
7.9, 4.6 Hz, 1H), 7.31 (d, J = 8.3 Hz, 2H), 7.14 (d, J = 8.1 Hz, 2H), 6.99 (dd, J = 8.0, 4.5 Hz, 
1H), 6.75 (br, 1H), 6.27 (br, 1H), 5.65 (br, 1H), 5.02 (d, J = 5.4 Hz, 2H), 4.91 – 4.72 (m, 2H), 
4.67 – 4.44 (m, 2H), 4.41 – 4.27 (m, 1H), 4.19 – 4.06 (m, 2H), 3.64 (s, 1H), 2.94 – 2.73 (m, 
3H), 2.65 (ddd, J = 17.0, 6.9, 2.6 Hz, 1H), 2.09 (t, J = 2.6 Hz, 1H), 1.78 – 1.66 (m, 2H), 1.59 
– 1.41 (m, 2H), 1.14 – 0.96 (m, 2H); HRMS (ES) C36H35N10O3F6 [M+H]
+ requires 769.2792, 
found 769.2796; purity by HPLC 91.0%, Rt = 9.561 min. 
In vitro anti-Wolbachia cell based screening  
Anti-Wolbachia activity was assessed in the A·WOL high content imaging (HCI) assayas 
described previously.(17) In brief this utilised a mosquito (Aedes albopictus) derived cell line 
(C6/36), stably infected with Wolbachia pipientis (wAlbB) with a read out of the percentage of 
the cells infected with Wolbachia. The EC50 values reported were the means of at least 5 
individual experiments. 
In vitro anti-Wolbachia Brugia malayi microfilaria (mf) assay and time-kill assay 
Brugia malayi mf were obtained from patently infected Meriones unguiculatus gerbils as 
described previously.(25) A series dilution of compounds (5 concentrations) were incubated 
with 8,000 mf/well (5 replicates), in RPMI supplemented with 10% FBS, 1% Penicillin 
Streptomycin and 1% Amphotericin B. After 6 days incubation (37 ⁰C, 5% CO2) motility was 
assessed by microscopy and DNA extracted for quantitative PCR (qPCR) analysis to obtain 
ratios of Wolbachia Surface Protein copy number (wsp) to Glutathione S-Transferase copy 
number (gst) as previously described.(26) Time kill assays were completed using the same 
method with the exception of a wash step on the indicated day. The drug concentration in 
the time-kill assay was 10 times of EC50. There were five replicates per time point per drug 
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treatment. The EC50 values or Wolbachia reduction percentages reported were from one 
individual experiment. 
In vitro drug metabolism/pharmacokinetic (DMPK) assays 
The DMPK properties data described above were measured once through a high through-
put platform provided by AstraZeneca U.K. The methods of the five assays, including 
LogD7.4, aqueous solubility, plasma protein binding, microsome and hepatocyte clearance 
measurements has been reported previously.(27, 28)   
In vivo anti-Wolbachia pharmacodynamic studies. 
Animals; for Brugia malayi studies, inbred male SCID CB.17 mice and outbred M. 
unguiculatus gerbil breeding pairs were purchased from Charles River, Europe. Rodents 
were maintained/bred in SPF conditions at the University of Liverpool Biological Services 
Unit. All experiments were approved by animal welfare ethics committees of the University of 
Liverpool and LSTM. Studies were conducted in accordance with Home Office legislation. 
Experiments with L. sigmodontis were performed at the Institute for Medical Microbiology, 
Immunology and Parasitology, University Hospital Bonn in accordance to the European 
Union animal welfare guidelines and all protocols were approved by the Landesamt für Natur, 
Umwelt und Verbraucherschutz, Cologne, Germany (AZ 84-02.04.2015.A507). Female M. 
unguiculatus gerbils were obtained from Janvier labs (Saint-Berthevin, France) and housed 
at the animal facility of the Institute for Medical Microbiology, Immunology and Parasitology 
in individually ventilated cages on a 12h light/dark cycle with food and water ad libitum. 
Filarial experimental infections; infectious stage B. malayi L3 were propagated as 
previously described.(14) Male mice 6-12 weeks of age (n=5-9) or male gerbils (n=6) 8-16 
weeks of age were infected with B. malayi L3 i.p. (50 or 100xL3 mouse, 400xL3, gerbil). 
Mouse experimental infections were maintained for 13 weeks whilst gerbil infections were 
maintained for maximum of 12 months. Motile B. malayi parasites were recovered by 
peritoneal lavage at necropsy and enumerated by microscopy. Motile mf from gerbil 
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infections were periodically isolated by intra-peritoneal catheter drain under anaesthesia with 
recovery as previously described.(14)  
For L. sigmodontis infection, 6-8 week old female gerbils were exposed to Ornithonyssus 
bacoti mites containing infective-stage L. sigmodontis L3. Treatment of microfilaraemic 
gerbils started 13 weeks following infection. Necropsies occurred 18 weeks following start of 
treatment. At necropsy, L. sigmodontis worms were isolated from the serous cavities and 
were quantified as previously described.(29) For mf counts, 10µl of peripheral blood were 
taken from the saphenous vein in bi-weekly intervals starting at 12 weeks post infection and 
diluted in 300µl of Hinkelmann solution (0.5% Eosin Y, 0.5% Phenol, 0.185% Formaldehyde 
in aqua dest). After centrifugation at 400g for 5 minutes, the supernatant was discarded; the 
pellet was resuspended in 1ml and transferred to a 1ml Sedgewick Rafter Counting 
Chamber to quantify total mf using a microscope. 
Drug dosing; infected animals were randomly assigned into dose groups (n = 5 - 9). 
AWZ1066S (or it HCl salt) was dissolved in PEG300/Propylene Glycol/H20 (55/25/20). 
Minocycline- and doxycycline-hyclate (Sigma-Aldrich) were dissolved in water. Animals were 
weighed and weight-corrected volumes of dosing solution administered by oral gavage 
(mouse: 100 l per 25 g body weight; gerbil: 2.5 ml/kg).   
Molecular assays; for B. malayi infections, determination of Wolbachia single-copy wsp 
gene quantity was undertaken by qPCR as previously described(14, 18) whereas, for L. 
sigmodontis, Wolbachia was determined by FtsZ qPCR as previously described.(30) 
Between 5 - 20 individual worms were assayed, derived from dose groups of 3 - 9 animals.  
Statistical analysis; continuous variables (Wolbachia loads, adult worm burdens, mf 
burdens) were tested for normal distribution by D'Agostino & Pearson omnibus normality 
tests pre- and post-Log10 transformation. Variables did not satisfy the assumption of 
normality and were compared by two-tailed Kruskal-Wallis Tests with Dunn’s Multiple Tests, 
post-hoc. Post-hoc testing scrutinized drug groups compared with vehicle or untreated 
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controls. Significance levels are indicated P<0.05*, P<0.01** P<0.001*** P<0.0001****. All 
statistics were undertaken using GraphPad Prism v6 software. 
PK/PD predictions of AWZ1066S activity in clinical settings; the predicted human 
pharmacokinetic parameters (SI Appendix Table S6) were used to predict the activity of 
AWZ1066S when administered in humans for 1 week using the simulator tool in 
Pmetrics™.(31) As previously described(21) we used a PK/PD model which links predicted 
human pharmacokinetic parameters with the observed in vitro activity of the drug against 
intracellular Wolbachia. 1000 subjects were simulated and % of subjects achieving >90% 
Wolbachia reduction at each week was recorded and data presented as a cumulative 
number of patients who achieve >90% Wolbachia load reduction. 
Preliminary target pulldown using photoreactive probes with Wolbachia infected cells. 
Please see Supplementary Information for experimental details of sample preparation and 
pull-down for proteomics, and LC-MS/MS analysis of proteomics samples and data 
processing. 
Figures 
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Figure 1 Medicinal chemistry optimisation to identify AWZ1066S including in vitro potency 
and DMPK properties. (a) Progression of the thienopyrimidine screening hit to the 
azaquinazoline candidate AWZ1066S through multi-parameter optimisation to improve 
potency and DMPK properties. (b) AWZ1066 treatment causes a dose-dependent reduction 
of Wolbachia from Wolbachia-infected cells. Images are visual representations of cells 
treated with doxycycline (top panel) and AWZ1066 (bottom panel), at various concentrations. 
In the cell-based assay C6/36 (wAlbB) cells are incubated with compounds, then stained 
with SYTO11 stain, which stains cell nuclei (large, bright areas, arrowhead) and Wolbachia 
(small, bright punctate staining, arrow) green. Automated capture and image analysis is 
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conducted by the Operetta and Harmony software (6 fields per well, two wells per 
concentration), which generates ‘percentage of infected cells’ values (shown in white, typical 
vehicle-treated cells have 70-80% infection, while doxycycline at maximum effect has 10-15% 
infection) that are used to calculate the effective concentration of 50% inhibition of 
Wolbachia (EC50, doxycycline = 20 nM and AWZ1066 = 2.6 nM). (c)  Anti-Wolbachia activity 
of AWZ1066S in the mf assay (EC50 = 121 nM) in comparison to the (R)-isomer AWZ1066R 
(EC50 = 408 nM). Doxycycline was used as positive control (EC50 = 300 nM). Data are 
expressed as mean ± s.d. of five replicates for each concentration. (d) In vitro DMPK related 
data of AWZ1066S presented in a radar plot. Six axes represent: human hepatocytes 
clearance (µl min-11X106 cells -1) (H. Hep. CL), human microsome clearance (µl min-1 mg-1) 
(H. Mic. CL), LogD7.4 (LogD), aqueous solubility in pH7.4 PBS buffer (µM) (Aq. sol.), 
permeability in LLC-PK1 cell assay (1 X 106 cm/s) (LLC Papp) and human plasma protein 
binding (%) (H. PPB). The light blue shaded area indicates the desired DMPK properties 
target ranges for oral administration. 
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Figure 2 In vivo anti-Wolbachia efficacy of AWZ1066S. Anti-Wolbachia efficacy against 
female adult stage B. malayi in SCID mice (a) or L. sigmodontis in gerbils (b) after 
doxycycline (DOX) minocycline (MIN) or AWZ1066S oral treatments at indicated doses. Tail 
and whisker plots are min, 25th, median, 75th and max Wolbachia wsp or ftsz copy 
number/female worm in samples of 5-24 worms derived from groups of 4-9 animals from an 
individual experiment. Significant differences compared with vechicle/untreated are indicated 
****P<0.0001, ***P<0.001, **P<0.01 (Kruskal-Wallis with Dunn’s tests for inter-group 
Wolbachia variation). (c) Longitudinal effects on circulating L. sigmodontis microfilaremias -1 
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to 18 weeks after DOX or AWZ1066S oral treatments at indicated doses in gerbils. (d) 
Result of PK/PD montecarlo prediction of clinical activity of AWZ1066S when dosed at 
600mg given predicted PK properties in man and established in vitro PD properties 
against Wolbachia. 
 
Figure 3 Unique mode-of-action of AWZ1066S was indicated by its fast kill-rate and was 
investigated through a proteomic target identification approach using two photoreactive 
chemical probes. (a) The Wolbachia depletion rates of AWZ1066S measured for three 
different treatment lengths (1, 2 and 6 days) in the Brugia malayi mf time-kill assay. 
Doxycycline, minocycline, moxifloxacin and rifampicin were used as positive controls (only 
doxycycline for day 1).  Data are expressed as mean ± s.d. of five replicates for each time 
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point. (b) Two photoreactive chemical probes used for target identification of AWZ1066S in 
Wolbachia. Structures (the bifunctional, photoreactive and clickable, side-chains are 
highlighted in red) and their anti-Wolbachia activity in the cell assay (n = 3). (c) 53 Putative 
protein targets of photoreactive probes 1 and 2 assigned (as showed in the Venn diagram) 
based on statistical testing (right-sided t-test, permutation based FDR=0.001, S0=3) of LFQ 
intensities measured in samples derived from probe-treated cells and control, DMSO-treated 
cells (n = 3). Protein targets presented in the left-hand side block are from Wolbachia 
pipientis and in the right-hand side block are from Aedes albopictus. Numbers within the 
heatmap legend represent Log2 LFQ t-test differences. Protein IDs above the heatmap 
given in red indicate 22 proteins identified as common targets of both probes.  
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